OR WAIT null SECS
Evonik completed a EUR 36 million expansion of its contract-manufacturing capabilities for API and advanced intermediates in the United States and Germany.
Evonik completed a EUR 36-million (US$42-million) expansion of its contract manufacturing capabilities in the United States and Europe, the company announced in a Sept. 19, 2018 press release. A series of advanced technologies, including high-potency API (HPAPI), fermentation, polyethylene glycol monomethyl ethers (mPEGs), and continuous processing have been introduced or enhanced at multiple Evonik production sites over the past year.
At its facility in Hanau, Germany, Evonik has recently commissioned a new modular cGMP continuous processing plant, a pilot plant for the custom synthesis of highly pure PEGs and mPEGs for pharmaceutical applications, and a cGMP suite for the small-scale production of HPAPI and ultra-HPAPI.
At its facilities in Tippecanoe, Indiana, US and Hanau, Germany, Evonik has increased its asset footprint and added additional capacities to support the small-, medium-, or large-scale production of HPAPI. Evonik is now able to run several HPAPI projects in parallel down to an occupational exposure level of 5 ng/m³.
At its facility in Slovakia, the company has recently invested in a new, flexible pilot plant for downstream processing. It is the sixth plant in a worldwide network to support microbial fermentation projects from strain development through to commercial manufacturing.
The Exclusive Synthesis team from Evonik will be at CPhI Worldwide in Madrid between October 9–11, 2018 at booth 9K20.